NasdaqCM:NKTRPharmaceuticals
Is Nektar (NKTR) Betting Its Immunology Future on Rezpegaldesleukin’s Ambitious ZENITH-AD Phase 3 Program?
Nektar Therapeutics recently launched preparations for its Phase 3 ZENITH-AD program for rezpegaldesleukin in atopic dermatitis, alongside presenting at the Jefferies Global Healthcare Conference 2026 and issuing inducement stock options to new hires under its 2025 Inducement Plan.
The move to start a five-trial Phase 3 program for rezpegaldesleukin, in an atopic dermatitis market facing entrenched competitors and biosimilars, could be a pivotal test of Nektar’s immunology-focused business...